Home › Funds › Bellevue Group AG › REGN

Bellevue Group AG position in REGN

REGENERON PHARMACEUTICALS · Health Care

Bellevue Group AG reported holding 157,291 shares of REGN (REGENERON PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$98.1M, representing 2.06% of its reported portfolio and ranking #15 among its reported holdings. Bellevue Group AG has disclosed REGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)157.29K sh
Reported value held$98.08M
Portfolio Weight2.06%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bellevue Group AG's REGN position evolved

Bellevue Group AG first disclosed a stake in REGN in Q3 2023 at 14,939 shares (US$12.3M). The position peaked in Q1 2026 at 278,674 shares, worth US$215.3M. Across 12 filings, Bellevue Group AG increased the stake 3 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 157,291 shares valued at US$98.1M — a reduction of -121,383 shares quarter over quarter.. Notable position changes include a 356% increase in Q2 2024 (shares were roughly flat over the following quarter), a 44% trim in Q3 2025 (shares rose 36% over the following quarter), a 1901% increase in Q1 2026 (shares fell 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 14.94K $12.29M New
Q4 2023 10.71K $9.41M Reduce
Q1 2024 7.08K $6.81M Reduce
Q2 2024 32.30K $33.95M Add
Q3 2024 26.78K $28.15M Reduce
Q4 2024 31.41K $22.38M Add
Q1 2025 28.52K $18.09M Reduce
Q2 2025 26.74K $14.04M Reduce
Q3 2025 15.06K $8.47M Reduce
Q4 2025 13.93K $10.75M Reduce
Q1 2026 278.67K $215.31M Add
Q2 2026 157.29K $98.08M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has Bellevue Group AG held REGN?

Bellevue Group AG has disclosed REGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Bellevue Group AG's current position in REGN?

As of Q2 2026, Bellevue Group AG holds 157.29K shares of REGN (REGENERON PHARMACEUTICALS), valued at $98.08M, representing 2.06% of its reported portfolio and ranking #15.

Has Bellevue Group AG been buying or selling REGN?

In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in REGN. The position peaked in Q1 2026 at 278.67K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.